iShares China Large-Cap ETF (FXI)

Key Updates

FXI rebounded 2.05% to $35.41 since the May 28 report, marking the first positive movement after three consecutive declining reports. This recovery partially offsets the regulatory-driven selloff, though YTD losses remain substantial at -7.51%. The modest rebound suggests investors are stabilizing positions following the brokerage crackdown, with no new material catalysts emerging during the period. The ETF continues to trade well below its year-opening levels, reflecting persistent structural headwinds despite improved U.S.-China diplomatic relations.

Current Trend

FXI remains in a confirmed downtrend with YTD losses of -7.51% and 6-month decline of -10.66%. The ETF has experienced heightened volatility, declining 2.53% (May 28), 2.59% (May 21), and 2.02% (May 15) in prior reports before the current 2.05% bounce. Short-term momentum shows mixed signals: up 1.04% over one day but down 0.30% over five days and 3.79% over one month. The current price of $35.41 remains significantly below levels seen during the Trump-Xi summit optimism in mid-May, indicating the market has not yet established a sustainable recovery trajectory. Support appears to be forming near the $34.70 level tested in late May, while resistance likely exists around the $36.50-37.00 range.

Investment Thesis

The investment thesis for FXI centers on China's economic stabilization, attractive valuations at 11x 2027 forecast earnings (half of U.S. multiples), and expected earnings growth of 15% matching American levels. Key structural supports include China's $20 trillion economy moving past its property crisis, record trade surpluses of $1.2 trillion in 2025, and growing technological innovation attracting corporate commitments like AstraZeneca's $15 billion pledge through 2030. The technology sector demonstrates particular strength, with AI-focused revenue surging 49% at Baidu and 132% at Zhipu. However, Beijing's regulatory actions to control capital outflows and redirect investment toward domestic markets represent a significant countervailing force, as evidenced by the crackdown on cross-border brokerages that must liquidate mainland accounts within two years.

Thesis Status

The investment thesis faces mounting challenges despite fundamental improvements. While economic stabilization and valuation arguments remain intact, Beijing's intensifying capital control measures directly contradict the thesis that improved U.S.-China relations would drive sustained inflows. The regulatory crackdown on Futu, Tiger Brokers, and Longbridge Securities demonstrates authorities prioritize domestic market control over foreign investment facilitation. Foreign direct investment of $80 billion in 2025—down from $344 billion in 2021—confirms persistent investor caution. The thesis retains validity for nimble, liquid investors who can exit quickly, as Reuters noted, but long-term conviction requires clearer policy signals. The 2.05% rebound suggests stabilization rather than thesis validation, as no new positive catalysts emerged beyond technical oversold conditions.

Key Drivers

The primary driver remains China's regulatory framework for capital flows. Beijing's crackdown on cross-border brokerages reflects authorities' determination to control the $176 billion official overseas investment quota against 171 trillion yuan in household savings. This structural constraint limits potential inflows to FXI regardless of valuation attractiveness. Positive drivers include UBS's bullish stance on Chinese tech stocks citing easing geopolitical tensions and strong AI ecosystem growth, with companies demonstrating robust earnings momentum. Morgan Stanley's upgraded price targets projecting 8-12% upside through Q2 2027 based on improved earnings and yuan appreciation provide institutional support. However, research showing Chinese acquisitions resulted in 1.1 percentage point ROA declines and concentrated investment through tax havens raises governance concerns that may limit institutional allocations.

Technical Analysis

FXI established a near-term support level at $34.70 during the May 28 session, which held during the latest period. The 2.05% rebound to $35.41 represents a technical bounce from oversold conditions rather than a trend reversal. Resistance exists at $36.50-37.00, corresponding to levels prior to the regulatory crackdown announcement. The ETF trades 10.66% below its 6-month high, with declining volume patterns suggesting weak conviction. The one-day gain of 1.04% contrasts with the five-day decline of 0.30%, indicating intraday volatility without sustained directional momentum. Short-term moving averages remain in bearish configuration, with the current price below both the 20-day and 50-day averages implied by the YTD and 6-month performance. A sustained move above $36.50 would be required to signal technical improvement, while a break below $34.70 would confirm continuation of the downtrend toward the $33.00-34.00 zone.

Bull Case

• Morgan Stanley projects 8-12% upside through Q2 2027 across major Chinese indexes based on improved earnings, strengthening global supply chain position, and yuan appreciation, with technology and green energy sectors aligned with China's 15th Five-Year Plan offering the strongest opportunities.
• Chinese equities trade at 11x 2027 forecast earnings with 15% expected growth—half U.S. valuations with matching growth rates—while the $20 trillion economy has stabilized past its property crisis and maintains record trade surpluses of $1.2 trillion, creating compelling risk-reward for nimble investors.
• China's AI ecosystem demonstrates exceptional growth momentum with Baidu reporting 49% surge in AI-focused revenue to 13.6 billion yuan and Zhipu posting 132% revenue growth in 2025, while UBS highlights easing U.S.-China geopolitical tensions allowing markets to refocus on strong fundamentals.
• China and Hong Kong ETFs received $1.22 billion in inflows following the Trump-Xi meeting, the largest among emerging markets, with global equity fund allocations to Chinese assets rising from 1.4% in early 2024 to 1.8% by February 2025, signaling renewed institutional interest.
• Major corporate commitments including AstraZeneca's $15 billion investment pledge through 2030 demonstrate multinational confidence in China's technological innovation trajectory beyond traditional manufacturing, supporting long-term structural growth despite near-term volatility.

Bear Case

• Beijing's regulatory crackdown on cross-border brokerages requiring mandatory liquidation of mainland accounts within two years and confiscation of illegal gains demonstrates authorities prioritize capital control over market liberalization, directly constraining potential inflows to offshore-listed Chinese equities including FXI.
• Foreign direct investment collapsed to $80 billion in 2025 from $344 billion peak in 2021, with private equity investors prioritizing liquid, easily-exitable positions due to ongoing concerns, while China's official overseas investment quota remains capped at only $176 billion against 171 trillion yuan in household savings.
• Research analyzing 161,773 firms shows Chinese acquisitions resulted in 1.1 percentage point decline in average ROA compared to non-Chinese owned firms, with nearly 40% of $3.3 trillion in global investments flowing through tax havens, raising governance and efficiency concerns that may limit institutional allocations.
• Major China-focused ETFs remain significantly below October highs with FXI down 11%, MCHI down 13.6%, and KWEB down 33%, while bellwether Alibaba declined 30% from its October peak despite Trump's China visit, indicating sustained structural headwinds beyond cyclical factors.
• Xi-Trump summit produced few concrete outcomes with Taiwan tensions reintroduced as geopolitical risk, while proposed tariff framework covers only $30 billion in goods—approximately 10% of China's exports to the U.S.—offering limited material impact on the broader $20 trillion economy and corporate earnings trajectory.